NYSE:PLX
Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc.'s revenue fell 1.2% in fiscal 2025 to $52.7M while operating margin fell to −10.4%. Free cash flow was −$13.6M, −25.8% of revenue, and the diluted share count fell 3.1%.Summary generated from Protalix BioTherapeutics, Inc.'s SEC filings. Latest annual report filed Mar 18, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$52.7M
Revenue growth−1.2%
Revenue, 5-yr CAGR−3.5%
Gross margin48.8%
Operating margin−10.4%
Net margin−12.5%
ROICn/a
Return on equity−14.4%
Debt / equityn/a
Free cash flow−$13.6M
FCF margin−25.8%
Share count change−3.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 38 | 48 | 65 | 53 | 53 |
| Operating income | −20 | −13 | 10 | 4 | −6 |
| Net income | −28 | −15 | 8 | 3 | −7 |
| Free cash flow | −12 | −26 | −2 | 7 | −14 |
Recent filings
- 4Insider transaction report
Sep 9, 2026 - 4Insider transaction report
Sep 4, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026 - 8-KResults of a shareholder vote
Jun 25, 2026 - 8-KRegulation FD disclosure
May 21, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 13, 2026 - 8-KResults of operations and financial condition
May 13, 2026